File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non–small cell lung cancer

TitleKEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non–small cell lung cancer
Authors
Issue Date2019
PublisherAmerican Association for Cancer Research. The Journal's web site is located at http://cancerres.aacrjournals.org/
Citation
Proceedings of the 110th American Association for Cancer Research (AACR) Annual Meeting, Atlanta, Georgia, USA. 29 March - 3 April 2019. In Cancer Research, 2019, v. 79 n. 13, Suppl., Abstract CT227 How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/279532
ISSN
2017 Impact Factor: 9.13
2015 SCImago Journal Rankings: 5.372

 

DC FieldValueLanguage
dc.contributor.authorGutierrez, M-
dc.contributor.authorHellmann, MD-
dc.contributor.authorGubens, MD-
dc.contributor.authorAggarwal, CA-
dc.contributor.authorTan, DSW-
dc.contributor.authorFelip, E-
dc.contributor.authorChiu, WYJ-
dc.contributor.authorLee, JS-
dc.contributor.authorYang, JCH-
dc.contributor.authorGaron, EB-
dc.contributor.authorBasso, AD-
dc.contributor.authorMa, H-
dc.contributor.authorFong, L-
dc.contributor.authorSnyder, A-
dc.contributor.authorYuan, J-
dc.contributor.authorHerbst, RS-
dc.date.accessioned2019-11-01T07:19:09Z-
dc.date.available2019-11-01T07:19:09Z-
dc.date.issued2019-
dc.identifier.citationProceedings of the 110th American Association for Cancer Research (AACR) Annual Meeting, Atlanta, Georgia, USA. 29 March - 3 April 2019. In Cancer Research, 2019, v. 79 n. 13, Suppl., Abstract CT227-
dc.identifier.issn0008-5472-
dc.identifier.urihttp://hdl.handle.net/10722/279532-
dc.languageeng-
dc.publisherAmerican Association for Cancer Research. The Journal's web site is located at http://cancerres.aacrjournals.org/-
dc.relation.ispartofCancer Research-
dc.relation.ispartofProceedings of the 110th American Association for Cancer Research (AACR) Annual Meeting-
dc.titleKEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non–small cell lung cancer-
dc.typeConference_Paper-
dc.identifier.emailChiu, WYJ: jwychiu@hku.hk-
dc.identifier.authorityChiu, WYJ=rp01917-
dc.identifier.doi10.1158/1538-7445.AM2019-CT227-
dc.identifier.hkuros308519-
dc.identifier.volume79-
dc.identifier.issue13, Suppl.-
dc.identifier.spageAbstract CT227-
dc.identifier.epageAbstract CT227-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats